AIDS Meds: Founded & Operated by People with HIVPOZ logo
Back to home » Treatment News » Top Stories

emailrssprint

Thymidine-Sparing Regimen Improves Lipoatrophy

November 30, 2006

By Will Boggs, MD

(Reuters Health) - Switching from a thymidine nucleoside analogue to tenofovir or abacavir can improve the loss of limb fat mass in HIV-infected patients with lipoatrophy, according to a report in the October 24th issue of AIDS.

"Switching helps lipoatrophy and maintains treatment benefits, but fat recovery is very slow, so prevention is always better," Dr. Graeme J. Moyle from Chelsea and Westminster Hospital, London, UK told Reuters Health.

Dr. Moyle and colleagues in the Randomized Abacavir versus Viread Evaluation (RAVE) group investigated the effects on limb fat of switching from a thymidine analogue to tenofovir DF as an alternative to abacavir, which has already been shown to improve lipoatrophy.

The trial involved 105 patients on successful antiretroviral therapy with moderate to severe lipoatrophy.

Median limb fat increased to a similar extent among tenofovir DF and abacavir recipients, the investigators report. Subcutaneous adipose tissue increased modestly over 48 weeks, but visceral adipose tissue showed no substantial change.

Patients who had been taking stavudine experienced greater increases in limb fat than did patients who had been taking zidovudine before the switch, the results indicate.

Lipid parameters improved after the switch to tenofovir DF, the researchers note, but there was no change after switching to abacavir.

Most laboratory markers remained unchanged after the switch from a thymidine analogue to tenofovir DF or abacavir, the team found, although tenofovir DF patients experienced significant increases in hemoglobin and patients in both groups had significant declines in plasma lactate levels.

"This study establishes tenofovir DF as an alternative to abacavir when switching from a thymidine analogue for lipoatrophy," the authors conclude. "Where feasible, consideration should be given to proactive switching away from thymidine analogue to either tenofovir DF or abacavir."

Dr. Moyle added, "I don't think the study suggests important differences between tenofovir DF and abacavir, so the choice is based on other considerations, such as cost."

AIDS 2006;20:2043-2050.



Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

emailrssprint



[Go to top]



Most Popular Stories

Spring Awakening: HIV, Allergies and Sinusitis

Evolutionary Accident Makes HIV Deadly

Hetero Men Also at Risk for Anal HPV

HIV Immunotherapy Shows Promise

Bad Teeth Also Bad for Young Men’s Hearts

Transplanting Hope: Stem Cell Experiment Raises Eyebrows at CROI


Most Popular Lessons

Herpes Simplex Virus

Syphilis & Neurosyphilis

Shingles

The HIV Life Cycle

Human Papilloma Virus (HPV)

What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Treatment News Archive

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006


© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy